WO2010053340A2 - Composition de blanchiment de la peau - Google Patents

Composition de blanchiment de la peau Download PDF

Info

Publication number
WO2010053340A2
WO2010053340A2 PCT/KR2009/006597 KR2009006597W WO2010053340A2 WO 2010053340 A2 WO2010053340 A2 WO 2010053340A2 KR 2009006597 W KR2009006597 W KR 2009006597W WO 2010053340 A2 WO2010053340 A2 WO 2010053340A2
Authority
WO
WIPO (PCT)
Prior art keywords
formula
skin
composition
final concentration
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2009/006597
Other languages
English (en)
Korean (ko)
Other versions
WO2010053340A3 (fr
Inventor
김청택
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RNS CO Ltd
Original Assignee
RNS CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020080110968A external-priority patent/KR101462692B1/ko
Priority claimed from KR1020080120364A external-priority patent/KR20100061978A/ko
Priority claimed from KR1020090083426A external-priority patent/KR20110025387A/ko
Application filed by RNS CO Ltd filed Critical RNS CO Ltd
Priority claimed from KR1020090108077A external-priority patent/KR20110051476A/ko
Publication of WO2010053340A2 publication Critical patent/WO2010053340A2/fr
Publication of WO2010053340A3 publication Critical patent/WO2010053340A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin

Definitions

  • the present invention relates to a cosmetic for skin whitening, and more particularly, cyclovirobuxine D, osthole, anomaline , Esculin, cardamonin, usnic acid, ordonin, oridonin, schizandrin B, curcumol, mollugin, wogo
  • the present invention relates to a nin (wogonin), a dihydromollugin compound, and a composition for skin whitening containing the same, and more particularly, to an external skin composition having an excellent whitening effect.
  • Melanogenesis is a defense mechanism against melanocyte melanocytes (melanocytes) that stimulate the production of melanin, which increases melanogenesis, which is transferred to keratinocytes and accumulated in the skin epidermis.
  • melanin protects the skin
  • hyperpigmentation of the skin causes blemishes, freckles, darkening of the skin after skin inflammation, and senile pigment spots. It may also result.
  • the melanin production process is made by tyrosinase, an amino acid called tyrosinase, which is transformed into dopa and dopaquinone, followed by a non-enzymatic oxidation reaction. It is known that spots, blotch, etc. are produced.
  • thiol-based compounds such as glutathione and cysteine not only have a characteristic unpleasant odor, but also have problems with transdermal absorption, and glycosides and derivatives thereof have high polarity, making it difficult to use as a cosmetic ingredient.
  • the present invention has no side effects on the skin, and excellent in inhibiting melanin production to provide a composition for skin whitening excellent in inhibiting skin pigmentation.
  • the present invention provides a melanin production inhibitor selected from the group consisting of compounds represented by the following formulas 1 to 12 excellent in melanin inhibitory effect and whitening effect.
  • the present invention also provides a skin whitening agent selected from the group consisting of the compounds represented by Formulas 1 to 12 and a composition for skin whitening containing any one or more of these as an active ingredient.
  • compositions such as cosmetics containing as a component can be used very effectively to improve skin hyperpigmentation, such as blemishes, freckles, aging spots and to realize skin whitening.
  • the present invention is cyclovirobuxine D of Formula 1 (Cyvivirobuxine D, C 26 H 46 N 2 O, CAS No. 860-79-7), Osthol (Formula 2, C 15 H 16 O 3 , CAS) No. 484-12-8), anmalin of Formula 3 (C 24 H 26 O 7 , CAS No. 81740-07-0), esculin of Formula 4 (C 15 H 16 O 9 , CAS No. 531-75-9), cardamonin of Formula 5 (C 16 H 14 O 4 , CAS No. 18956-16-6), usnic acid of Formula 6 (C 18 H 16 O 7 , CAS No. 125-46-2), orridinin (C20H28O6, CAS No.
  • the present inventors conducted a new whitening agent study on native plants and animals using B16 mouse melanoma cells capable of screening even substances that inhibit melanin synthesis induction.
  • the compounds of compounds 1 to 5 have been found to have a very strong melanin production inhibitory effect and a whitening effect to complete the present invention.
  • the compounds of Formulas 1 to 12 mentioned above may be easily purchased on the market, or each may be used alone or in combination of two or more kinds thereof, such as skin, lotion, cream, foundation, essence, gel, pack, foam cleansing, soap, etc.
  • An effective amount may be added to various compositions such as ointments to exhibit skin lightening effects.
  • the amount of the compound added is preferably 0.00001 to 10% by weight based on the total weight of the composition, more preferably 0.001 to 1.0% by weight.
  • Table 1 sample Melanin production % Inhibition Control group (no addition) 0.044 ⁇ 0.004 - arbutin (final concentration 300 ⁇ g / ml) 0.028 ⁇ 0.004 36 cyclovirobuxine D (final concentration 5 ⁇ g / ml) 0.019 ⁇ 0.003 57 cyclovirobuxine D (final concentration 20 ⁇ g / ml) 0.012 ⁇ 0.002 73 osthole (final concentration 5 ⁇ g / ml) 0.038 ⁇ 0.001 14 osthole (final concentration 20 ⁇ g / ml) 0.028 ⁇ 0.003 36 anomalin (final concentration 5 ⁇ g / ml) 0.025 ⁇ 0.002 43 anomalin (final concentration 20 ⁇ g / ml) 0.018 ⁇ 0.002 59 esculin (final concentration 5 ⁇ g / ml) 0.036 ⁇ 0.002 18 esculin (final concentration 20 ⁇ g / m
  • the compounds of Formulas 1 to 12 showed excellent melanin production inhibitory activity even at low concentrations against melanoma cells of cultured rats, compared with arbutin, a whitening substance known in the art, and cytotoxicity Did not appear. This indicates that the present invention can be very useful for improving blemishes and freckles and skin whitening.
  • the external application ointment of Preparation Examples 1 to 12 showed a whitening effect on at least 12 of 20 subjects, and showed no side effects in the skin and was safe and improved freckles and freckles. It can be seen that the skin whitening agent has an excellent effect on.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne un produit cosmétique de blanchiment de la peau contenant un composé présentant une activité inhibant la production de mélanine. La composition de blanchiment de la peau décrite dans l'invention présente la caractéristique de contenir au moins un composant actif sélectionné dans le groupe comprenant la cyclovirobuxine D, l'osthole, l'anomaline, l'esculine, la cardamonine, l'acide usnique, l'oridonine, la schizandrine B, le curcumol, la mollugine, la wogonine, la dihydromollugine et des mélanges de ceux-ci. Les composés de la présente invention inhibent la production de mélanine et sont particulièrement efficaces pour gêner le dépôt pigmentaire. Ainsi, une composition telle qu'un produit cosmétique contenant un ou plusieurs de ces composés en tant que composant actif peut être utilisée de manière extrêmement efficace pour le blanchiment de la peau, par exemple, pour estomper les tâches de vieillesse et les tâches de rousseur.
PCT/KR2009/006597 2008-11-10 2009-11-10 Composition de blanchiment de la peau Ceased WO2010053340A2 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
KR10-2008-0110968 2008-11-10
KR1020080110968A KR101462692B1 (ko) 2008-11-10 2008-11-10 피부미백용조성물
KR1020080120364A KR20100061978A (ko) 2008-12-01 2008-12-01 피부미백용조성물
KR10-2008-0120364 2008-12-01
KR10-2009-0083426 2009-09-04
KR1020090083426A KR20110025387A (ko) 2009-09-04 2009-09-04 피부미백용조성물
KR10-2009-0108077 2009-11-10
KR1020090108077A KR20110051476A (ko) 2009-11-10 2009-11-10 피부미백용조성물

Publications (2)

Publication Number Publication Date
WO2010053340A2 true WO2010053340A2 (fr) 2010-05-14
WO2010053340A3 WO2010053340A3 (fr) 2010-07-08

Family

ID=42153426

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/006597 Ceased WO2010053340A2 (fr) 2008-11-10 2009-11-10 Composition de blanchiment de la peau

Country Status (1)

Country Link
WO (1) WO2010053340A2 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101244138B1 (ko) 2011-04-29 2013-03-14 주식회사 엘지생활건강 상피세포 성장인자 생성 촉진용 조성물
US20140107081A1 (en) * 2011-03-31 2014-04-17 Evocutis Plc Salicylic acid topical formulation
KR101502545B1 (ko) * 2013-06-19 2015-03-13 주식회사 엘지생활건강 아노말린을 포함하는 피부 볼륨증가 및 주름개선용 화장료 또는 약학 조성물
CN104770362A (zh) * 2015-03-12 2015-07-15 西北农林科技大学 五味子乙素用于制备猪精液保存用稀释液的应用
KR101560460B1 (ko) 2013-12-04 2015-10-15 영남대학교 산학협력단 퓨로몰루긴 또는 이의 유도체를 유효성분으로 함유하는 조성물
WO2015167239A1 (fr) * 2014-04-30 2015-11-05 (주)아모레퍼시픽 Composition contenant de l'extrait d'impératoire
KR101569772B1 (ko) * 2014-01-08 2015-11-17 주식회사 엘지생활건강 우고닌 또는 이의 약학적으로 허용 가능한 염을 포함하는 다크서클 개선용 화장료 조성물
KR101578461B1 (ko) 2014-05-12 2015-12-18 한국콜마주식회사 멜라닌 생성억제능의 쿠마린계 화합물로 이루어진 피부 미백제, 그를 함유하는 피부 미백용 조성물 및 상기 쿠마린계 화합물의 분리방법
KR20160001949A (ko) * 2014-06-30 2016-01-07 (주)아모레퍼시픽 산형화 추출물을 포함하는 미백용 조성물
KR101873884B1 (ko) * 2011-09-01 2018-07-04 (주)아모레퍼시픽 에스쿨린 유도체를 포함하는 피부 미백용 조성물

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108186653B (zh) * 2018-03-28 2019-10-18 苏州大学 环维黄杨星d抗登革病毒的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080254130A1 (en) * 2003-08-29 2008-10-16 Bioderm Research Skin Antiaging & Brightening via Multi-function Treatment of Enzyme Dysfunction
ES2384878T3 (es) * 2003-11-07 2012-07-13 Basf Beauty Care Solutions S.A.S. Uso cosmético de un extracto de la fruta de Schisandra chinensis
JPWO2005084613A1 (ja) * 2004-03-04 2008-01-17 株式会社 ベリタス 皮膚外用剤
US20050271608A1 (en) * 2004-06-05 2005-12-08 Gupta Shyam K Skin whitening compositions based on hydroxyaryl alkyl ketones and their isosteric derivatives
KR100760875B1 (ko) * 2006-06-21 2007-10-04 부경대학교 산학협력단 멜라닌 생성 억제 피부미백용 화장품 조성물

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140107081A1 (en) * 2011-03-31 2014-04-17 Evocutis Plc Salicylic acid topical formulation
KR101244138B1 (ko) 2011-04-29 2013-03-14 주식회사 엘지생활건강 상피세포 성장인자 생성 촉진용 조성물
KR101873884B1 (ko) * 2011-09-01 2018-07-04 (주)아모레퍼시픽 에스쿨린 유도체를 포함하는 피부 미백용 조성물
KR101502545B1 (ko) * 2013-06-19 2015-03-13 주식회사 엘지생활건강 아노말린을 포함하는 피부 볼륨증가 및 주름개선용 화장료 또는 약학 조성물
KR101560460B1 (ko) 2013-12-04 2015-10-15 영남대학교 산학협력단 퓨로몰루긴 또는 이의 유도체를 유효성분으로 함유하는 조성물
KR101569772B1 (ko) * 2014-01-08 2015-11-17 주식회사 엘지생활건강 우고닌 또는 이의 약학적으로 허용 가능한 염을 포함하는 다크서클 개선용 화장료 조성물
WO2015167239A1 (fr) * 2014-04-30 2015-11-05 (주)아모레퍼시픽 Composition contenant de l'extrait d'impératoire
KR101578461B1 (ko) 2014-05-12 2015-12-18 한국콜마주식회사 멜라닌 생성억제능의 쿠마린계 화합물로 이루어진 피부 미백제, 그를 함유하는 피부 미백용 조성물 및 상기 쿠마린계 화합물의 분리방법
WO2016003117A1 (fr) * 2014-06-30 2016-01-07 (주)아모레퍼시픽 Composition de blanchiment comprenant un extrait d'ombelle
KR20160001949A (ko) * 2014-06-30 2016-01-07 (주)아모레퍼시픽 산형화 추출물을 포함하는 미백용 조성물
CN106470693A (zh) * 2014-06-30 2017-03-01 株式会社爱茉莉太平洋 含大星芹提取物的用于美白肌肤的组合物
TWI685355B (zh) * 2014-06-30 2020-02-21 南韓商愛茉莉太平洋股份有限公司 以大星芹（Peucedanum Ostruthium）萃取物製備組成物作為美白肌膚、減少黑色素及抑制色素沉著的用途
CN104770362A (zh) * 2015-03-12 2015-07-15 西北农林科技大学 五味子乙素用于制备猪精液保存用稀释液的应用

Also Published As

Publication number Publication date
WO2010053340A3 (fr) 2010-07-08

Similar Documents

Publication Publication Date Title
WO2010053340A2 (fr) Composition de blanchiment de la peau
KR100855457B1 (ko) 악틴, 악티게닌 또는 그의 혼합물을 유효성분으로 함유하는피부미백용 화장료 조성물
JP5562513B2 (ja) パラ−クマル酸すなわちパラ−ヒドロキシ桂皮酸誘導体類および化粧品または皮膚科組成物中でのそれらの使用
JP2749218B2 (ja) 美白用化粧料組成物
KR101919616B1 (ko) 피부미백용조성물
KR20140033815A (ko) 퀴닉산 유도체 및 그의 용도
KR100760875B1 (ko) 멜라닌 생성 억제 피부미백용 화장품 조성물
KR100538866B1 (ko) 알로에신 유도체의 합성방법
KR100454736B1 (ko) 베라트라민을 함유하는 피부미백용 조성물
KR101462692B1 (ko) 피부미백용조성물
KR20100061978A (ko) 피부미백용조성물
KR20160028930A (ko) 피부미백용조성물
KR100757130B1 (ko) 멜라닌 생성 억제 활성을 갖는 베라진 및 에피-베라진을함유하는 피부미백용 화장료
KR100466379B1 (ko) 피부미백용 조성물
KR100602684B1 (ko) 망초 추출물을 유효성분으로 함유하는 미백용 화장료조성물
KR20130089559A (ko) 항노화 조성물
KR102852940B1 (ko) 1,3-디옥틸옥시벤젠을 유효성분으로 포함하는 피부 미백용 조성물
KR102160306B1 (ko) 피부미백제
KR20220099259A (ko) 홍화씨유 가수분해물과 삼백초 추출물의 혼합물을 유효성분으로 함유하는 피부미백용 조성물
KR101786606B1 (ko) 테트란드린을 함유하는 화장료 조성물
KR20110051476A (ko) 피부미백용조성물
KR20100016815A (ko) 돌나물 추출물 및 알부틴을 함유하는 미백 화장료 조성물
KR101832415B1 (ko) 레티노이드 유도체를 유효성분으로 함유하는 피부 미백용 화장료 조성물
KR20010088120A (ko) 식물 추출물을 함유하는 미백 화장료 조성물
KR20090105492A (ko) 아사이베리 추출물을 유효 성분으로 함유하는 미백 화장료조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09825023

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09825023

Country of ref document: EP

Kind code of ref document: A2